Add Company
Join Now

CRS Revenue and Competitors

License our Company Data API

Location

N/A

Total Funding

Environmental

Industry

Estimated Revenue & Valuation

  • CRS's estimated annual revenue is currently $6.6M per year.(i)
  • CRS's estimated revenue per employee is $168,000

Employee Data

  • CRS has 39 Employees.(i)
  • CRS grew their employee count by 5% last year.

CRS's People

NameTitleEmail/Phone
1
Director, Certification ProgramsReveal Email/Phone
2
Director, PolicyReveal Email/Phone
3
Director, Technical ProjectsReveal Email/Phone
4
Chief Financial and Administrative OfficerReveal Email/Phone
5
Executive DirectorReveal Email/Phone
6
Director, PolicyReveal Email/Phone
7
Senior Manager, Standards and Technical AssistanceReveal Email/Phone
8
Manager, Events and EducationReveal Email/Phone
9
Senior Manager, Program OutreachReveal Email/Phone
10
ManagerReveal Email/Phone
Competitor NameRevenueNumber of EmployeesEmployee GrowthTotal FundingValuation
#1
$3.8M26-10%N/AN/A
#2
$6.4M38-12%N/AN/A
#3
$428.2M142641%$5.6MN/A
#4
$2.1M1713%N/AN/A
#5
$104.2M3977%N/AN/A
#6
$42.9M1903%N/AN/A
#7
$59.8M2597%N/AN/A
#8
$3.4M2310%N/AN/A
#9
$6.6M39-7%N/AN/A
#10
$5.9M35-36%N/AN/A
Add Company

What Is CRS?

Center for Resource Solutions (CRS) creates policy and market solutions to advance sustainable energy. We're a national nonprofit with global impact. CRS brings forth expert responses to climate change issues with the speed and effectiveness necessary to provide real-time solutions. Our leadership through collaboration and environmental innovation builds policies and consumer-protection mechanisms in renewable energy, greenhouse gas reductions, and energy efficiency that foster healthy and sustained growth in national and international markets.

keywords:N/A

N/A

Total Funding

39

Number of Employees

$6.6M

Revenue (est)

5%

Employee Growth %

N/A

Valuation

N/A

Accelerator

CRS News

2022-04-20 - Surveyed Patients Identify Unmet Needs in CRS With Nasal Polyps

Patients with chronic rhinosinusitis (CRS) with nasal polyps identified several unmet needs regarding their condition, particularly a lack...

2022-04-17 - SEC Settles with 12 Firms for Incomplete CRS Obligations

(See SEC Staff Statement Highlights Need for Form CRS Disclosure Improvements, available here.) The SEC's press release announcing the...

2022-04-06 - Can Anakinra Spare Tocilizumab in Management of CAR T-Cell CRS?

Finding an effective alternative or adjunctive treatment for CRS is critical, given that CRS is a common and potentially fatal complication...

Company NameRevenueNumber of EmployeesEmployee GrowthTotal Funding
#1
$4.1M39-17%$100.3M
#2
$7.8M39-54%N/A
#3
$4.4M39-15%N/A
#4
$6.6M39-28%N/A
#5
$4.1M39-17%$89.2M